Author: NWN
After years of randomized trials and nearly two decades of European data detailing peptide receptor radionuclide therapy, Advanced Accelerator Applications (AAA), a Novartis company, is pleased to announced that the FDA has approved the use of this therapy for patients…
On January 14, 2018, Dr. Thor Halfdanarson and Dr. A. Tuba Kendi from Mayo Clinic Rochester presented to Northwoods NETS. Dr. Tuba, a radiologist from Mayo, has been fronting the Gallium-68 PET/MRI scan center that has been helping detect and…
Happy New Year to all of our NET patients, caregivers, family members, medical support teams and friends around the world. Twenty eighteen is going to be a fantastic year!
Northwoods NETS is pleased to announce that Senator Mark Dayton has proclaimed Friday, November 10th, NET Cancer Awareness Day in the state of Minnesota. We thank Governor Dayton for his continued recognition of this unusual cancer. It is estimated that…
We are about a month away from NET Cancer Day, an international awareness day to help shine a light on neuroendocrine cancers. There are many ways you can help to make an impact on this upcoming NET Cancer Day: Talk to…
Advanced Accelerator Applications S.A. (AAA) has announced that the Food and Drug Administration (FDA), in the United States, has accepted and considered complete the resubmission of the New Drug Application (NDA) for its investigational drug lutetium Lu 177 dotatate (Lutathera). Lutathera…
Recently, while aimlessly browsing on the Internet, I discovered a website that was trying to encourage Google to make November 10th a Google Doodle to help raise awareness of NET Cancer Day. I don’t recall that happening, ever. I figure it’s…
A new paper has recently been released in Digestion: International Journal of Gastroenterology that reviewed previously reported European trials. These trials specifically aimed at the treatment of advanced pancreatic neuroendocrine tumors outlined several combinations of chemotherapy drugs used to help with…
We have exciting news in regards to Peptide Receptor Radionuclide Therapy (PRRT) therapy in the United States. Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). Considering that Phase III NETTER-1 clinical trial recruitment has been completed, this expanded…
It’s not often that we have a reason to discuss reality television shows here on Northwoods NETS, but, we have a notable exception right now. The Voice contestant, Felicia Temple, 28, is also a neuroendocrine tumor patient. An amazing vocalist and…
